Company Focus
Bristol Myers Squibb
Latest Bristol Myers Squibb News
Pharmaceutical
US pharma major Bristol Myers Squibb revealed it has appointed Dr Cristian Massacesi as executive vice president, chief medical officer and head of development, effective August 1, 2025. 26 July 2025
Related News
Insights
Company Spotlight
A UK-based biotech company developing a therapeutic platform for treating aggressive cancers.
Latest News & Features of interest to Bristol Myers Squibb
Biotechnology
The European Commission has approved Swiss pharma giant Roche’s Itovebi (inavolisib), in combination with palbociclib (Ibrance) and fulvestrant, for the treatment of adult patients with PIK3CA-mutated, oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, following recurrence on or within 12 months of completing adjuvant endocrine treatment. 23 July 2025
Biotechnology
Scancell Holdings, the developer of Immunobody and Moditope active immunotherapies to treat cancer, has announced further positive data from the ongoing Phase II SCOPE trial of SCIB1/iSCIB1+ Immunobody DNA active immunotherapies in combination with checkpoint inhibitors in advanced unresectable melanoma. 23 July 2025
Biotechnology
Cambridge, USA-based biotech Avalyn Pharma, which developing inhaled therapies for the treatment of life-threatening pulmonary diseases, has announced the closing of an oversubscribed $100 million Series D financing. 23 July 2025
Pharmaceutical
French pharma Ipsen (Euronext: IPN) today announced the following changes to its executive committee: 23 July 2025
Biotechnology
Patients in the UK will now be able to access advanced, personalized treatments prepared at the hospital or even in mobile units near their homes, thanks to a world-first regulatory shift. New legislation introduced by the country’s drug regulator allows hospitals and care centers to produce small or individual batches of cutting-edge therapies at the point of care. 23 July 2025
Generics
Swiss pharma Sandoz has spent less than a year charting its course as an independent company, but already it’s moving with the confidence of a seasoned player. Since separating from former parent Novartis in October 2023, the generics and biosimilars specialist has been working fast to reshape its identity—and its balance sheet. 22 July 2025
Biotechnology
French biotech ImCheck Therapeutics has announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to its lead program, ICT01, a humanized anti-butyrophilin 3A (BTN3A) monoclonal antibody designed to selectively activate γ9δ2 T cells, in acute myeloid leukemia (AML). 22 July 2025
Biotechnology
Shares in Replimune Group, a US biotech developing novel oncolytic immunotherapies, went in freefall Tuesday, as the company announced a major setback. 22 July 2025
Pharmaceutical
Neuraxpharm Group, a privately-held German specialty pharma focused on central nervous system (CNS) disorders, today announced the launch of a new affiliate, Neuraxpharm Australia, led by newly appointed head of commercial, Avendran Naidu, as the company continues to expand globally. 22 July 2025
Pharmaceutical
Ireland-based Alkermes has announced positive topline results from the randomized double-blind treatment period of the Vibrance-1 Phase II study evaluating alixorexton in patients with narcolepsy type 1 (NT1). 22 July 2025
Latest In Brief for Bristol Myers Squibb
Biotechnology
US biotech Nanoscope Therapeutics has begun a rolling submission to the American medicines regulator for MCO-010, the first gene-agnostic therapy seeking approval for retinitis pigmentosa (RP). 15 July 2025
Latest Relevant Ones To Watch News
French pharma major Sanofi today announced it has entered into an agreement to acquire Vicebio, a privately held biotechnology company headquartered in London, UK. 22 July 2025
18 July 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze